Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Lack of HIV transmission after hepatitis B immunoprophylaxis

  • 14 Accesses

This is a preview of subscription content, log in to check access.


  1. 1.

    Godke, D. J., Raska, K., Pollack, W., Schwartzer, T. HTLV-III antibody in commercial immunoglobulin. Lancet I (1986) 37–38.

  2. 2.

    Tedder, R. S., Uttley, A., Cheingsong-Popov, R. Safety of immunoglobulin preparation containing anti-HTLV-III. Lancet I (1985) 815.

  3. 3.

    Centers for Disease Control Safety of therapeutic immunoglobulin preparations with respect to transmission of human T cell lymphotropic virus type III/lymphadenopathy associated virus infection. MMWR 35 (1986) 271–272.

  4. 4.

    Wells, M. A., Wittek, A. E., Epstein, J. S., Markus-Cekura, C., Daniel, S., Tankersley, D. L., Preston, M. S., Quinnan, G. V. Inactivation and partition of human T cell lymphotropic virus type III during ethanol fractionation of plasma. Transfusion 26 (1986) 210–213.

  5. 5.

    Prince, A. M., Piët, M. P. J., Horowitz, B. Effect of Cohn fractionation conditions on infectivity of the AIDS virus. N. Engl. J. Med. 314 (1986) 386–387.

  6. 6.

    Muylle, L., Vranckx, P., Peetermans, M. E. No HTLV-III antibodies after HBV vaccination. N. Engl. J. Med. 314 (1986) 581.

Download references

Author information

Correspondence to J. Genescà M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Genescà, J., Esteban, J.I., Esteban, R. et al. Lack of HIV transmission after hepatitis B immunoprophylaxis. Infection 15, 366 (1987). https://doi.org/10.1007/BF01647744

Download citation


  • Public Health
  • Hepatitis
  • Internal Medicine
  • Infectious Disease
  • General Practice